Patients with advanced primary and recurrent salivary duct carcinoma (SDC), a rare and lethal malignancy, have limited therapeutic options. Novel small-molecule agents aimed at targeting critical signaling associated with SDC tumorigenesis may lead to new therapeutic options for patients with these tumors. The human epidermal growth factor receptor 2 (HER2)/phosphoinositide 3-kinase (PI3K) axis, an important oncogenic pathway, has been targeted for therapy in several solid tumors. Currently, little is known about the role and clinical implications of alterations of the HER2/PI3K pathway in patients with SDC. METHODS: The authors investigated the clinicopathologic features, genetic alterations, and expression of key members of the HER2/PI3K pathway in 43 primary tumors and conducted in vitro functional and targeted drug-response analyses on cell lines derived from salivary epithelial carcinomas. RESULTS: In primary tumors, loss of phosphatase and tensin homolog (PTEN) expression was identified in 22 of 43 tumors (51%), overexpression of HER2 was observed in 12 of 43 tumors (28%), and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations were identified in 12 of 43 tumors (28%). Phosphorylated protein kinase B (p-AKT) was highly expressed in most tumors. Most tumors (70%) displayed mutually exclusive alterations of PI3K members, whereas 8 tumors (19%) had 2 or more concurrent abnormalities. In vitro studies demonstrated a direct association between PTEN loss and PI3K pathway activation and evidence of response to combined PI3Kα and PI3Kβ and/or pan-PI3K inhibitors. CONCLUSIONS: The current analyses reveal frequent PTEN loss and mutually exclusive alterations of key PI3K pathway members in SDC and demonstrate in vitro evidence of a response to pan-PI3K inhibitors. These results provide a framework for a biomarker-based substratification of patients with SDC in future targeted therapy. Cancer 2018;124:3693-3705.
INTRODUCTION
Salivary duct carcinoma (SDC), a rare and highly aggressive ductal epithelial malignancy of salivary glands, commonly presents at an advanced stage in elderly patients of both sexes. 1 Histologically, both de novo SDCs and those arising in carcinoma ex pleomorphic adenoma display malignant epithelial cell proliferation, forming glandular, cribriform, micropapillary, and nesting structures. [2] [3] [4] [5] The primary treatment for SDC is complete surgical removal with lymph node dissection and postoperative radiotherapy and/or chemotherapy. Patients with advanced unresectable primary, recurrent, and metastatic disease have limited therapeutic options and empirically receive treatment with taxane-based and/or targeted agents. 6, 7 SDCs also share common morphologic and biologic characteristics with other salivary adenocarcinoma subtypes and ductal mammary carcinoma, [8] [9] [10] [11] [12] including alterations of the phosphoinositide 3-kinase (PI3K) pathway. [11] [12] [13] [14] [15] [16] In contrast to mammary carcinoma, however, functional and therapeutic studies of the PI3K pathway in SDCs and other salivary adenocarcinomas have been limited, largely because of lack of cell lines and
Cancer September 15, 2018 animal models of this phenotype. 17, 18 We hypothesized that an assessment of the differential alterations and functional consequences of key members of the PI3K pathway might lead to better stratification of patients with SDCs and other forms of adenocarcinomas for targeted therapy.
The PI3K/protein kinase B (AKT) pathway and human epidermal growth factor receptor 2 (HER2) signaling play critical roles in regulating vital cellular processes, including proliferation, survival, and motility. Overexpression of HER2, an upstream receptor tyrosine kinase, has been linked to activation of the PI3K pathway in mammary ductal carcinoma and other epithelial malignancies. [12] [13] [14] [15] [16] [17] [18] PI3K consists of a heterodimer of an 85-kDa regulatory subunit and a 110-kDa catalytic subunit, including phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), -beta (PIK3CB), or -delta (PIK3CD), that can be activated by receptor tyrosine kinases through the phosphorylation of phosphatidylinositol-4,5-biphosphate phosphates to phosphatidylinositol-3,4,5-trisphosphate, which recruits 3-phosphoinositide dependent protein kinase 1 at the cell membrane to induce downstream effectors. 19, 20 The catalytic activity of PI3K, which is negatively regulated by phosphatase and tensin homology (PTEN), leads to the up-regulation of phosphorylated AKT (p-AKT) and the stimulation of critical cellular functions, including cell proliferation, migration, survival, and differentiation. 21, 22 The objectives of the current study were: 1) to determine the incidence and the role of key members of the PI3K pathway in patients with SDC who were managed at a single institution; and 2) for the first time, to determine the functional and therapeutic implications of PI3K alterations in cell lines developed from salivary epithelial carcinomas.
MATERIALS AND METHODS

Primary Salivary Duct Carcinomas
A search of the head and neck tumor bank at The University of Texas MD Anderson Cancer Center (MD Anderson) for patients who had SDC (either de novo or arising in carcinoma ex pleomorphic adenoma) who received primary treatment at our institution identified 43 patients for whom we had demographic and clinicopathologic information. Of these 43 patients, 25 had been included in a previous publication 23 (see Supporting  Table 1 ). This study was approved by the MD Anderson Institutional Review Board, and all patients provided written informed consent for genomic and molecular analyses.
PIK3CA, PTEN, and AKT1 Gene Mutation Analysis
Genomic DNA was extracted from tumor tissue samples that had >70% tumor cells using the Gentra Puregene tissue kit (QIAGEN, Valencia, CA) according to the manufacturer's instructions. The primer locations for PIK3CA, PTEN, and AKT1 gene mutation analyses were determined in reference to the Catalog of Somatic Mutations in Cancer (COSMIC, V75) database (http:// cancer.sanger.ac.uk/cosmic). Genomic DNA was amplified by polymerase chain reaction (PCR) using KAPA 2G fast (KAPA Biosciences, Inc, Wilmington, MA). PCR primer sets are presented in Supporting Table 2 . All PCR products were purified using Exo-Sup and subsequently underwent Sanger sequencing using a 3730x1 DNA Analyzer (Applied Biosystems, Foster City, CA) at the MD Anderson sequencing and microarray facility.
Western Blot Analysis
Cell lines and fresh tumor tissues were lysed using a radioimmunoprecipitation assay buffer containing freshly added protease (no. 0505648900; Roche Applied Science, Penzberg, Germany) and phosphatase (no. 04906837001; Roche Applied Science) inhibitor cocktails. Aliquots of 20 mg protein lysate were loaded into sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and transferred onto a nitrocellulose membrane. The blots was probed with anti-PTEN (138G6, rabbit; Cell Signaling Technology, Danvers MA), anti-p-AKT (Ser473, clone D9E, rabbit; Cell Signaling Technology), anti-HER2 (clone D8F12, rabbit; Cell Signaling Technology), and anti-β-Actin (AC-15, mouse; Sigma-Aldrich, St Louis, MO) antibodies.
Immunohistochemistry
Immunohistochemical (IHC) analysis was performed using 4-μm-thick, unstained tissue microarray sections on an Autostainer Link 48 (Dako-Agilent Pathology Solutions, Carpinteria, CA) according to the manufacturer's instructions. After incubation with the primary antibodies to HER2 (clone e2-4001, mouse; 1:300 dilution; Thermo Fisher Scientific, Waltham, MA), PTEN (clone 6H2.1, mouse; 1:100 dilution; Dako-Agilent Pathology Solutions), or p-AKT (Ser473, clone D9E, rabbit; 1:100 dilution; Cell Signaling Technology), the secondary antibody was applied. HER2 was evaluated for the extent and intensity of membranous and cytoplasmic expression
Cancer September 15, 2018 as strong, complete staining (score, + 3) in > 10% of tumor cells; moderate, membranous staining (score, + 2) in > 10% of tumor cells; weak, partial staining (score, + 1) in > 10% of tumor cells; and the complete absence of staining (negative; score, 0). Only strong, complete membranous staining (score, + 3) was used to define tumors as positive for HER2. 10, 14, 15, 24 PTEN expression was scored in a binary fashion as negative (complete loss) and positive (cytoplasmic and/or nuclear staining) in tumor cells. P-AKT cytoplasmic expression was evaluated based on a binary scale in which scores of 0 and +1 were considered low expression, and scores of +2 and +3 were considered high expression. 23 The MAC cell line was developed from a salivary mucinous adenocarcinoma (salivary duct and other adenocarcinomas can also manifest mucinous differentiation). 4, 5, 27 The A253 cells were maintained in Dulbecco's modified Eagle medium with 10% fetal bovine serum (Thermo Fisher Scientific) and RET981 and MAC cells were maintained RPMI 1640 medium (Thermo Fisher Scientific) with 10% fetal bovine serum using standard cell culture techniques. The prostate cancer cell line LNCaP (ATCC) was used as a PTEN loss control and was maintained in RPMI 1640 medium with 10% fetal bovine serum. For a cellular viability assay to monitor drug toxicity, AZD8186 (PI3Kβ/PI3Kδ inhibitor; Active Biochem LTD, Hong Kong, China), GSK2636771 (PI3Kβ inhibitor; Selleckchem, Houston, TX), BYL719 (PI3Kα inhibitor; Selleckchem), and GDC-0941 (PI3Kα/PI3Kβ/ PI3Kγ/PI3Kδ inhibitor; Selleckchem) were assessed using a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Briefly, cells were seeded at 5000 cells per well in 96-well plates and were exposed to drugs after 24 hours (day 0). MTT assays were performed at 0, 1, 2, 4 days after addition of the drugs.
In Vitro Cell Line Studies
PTEN Knockdown Study
PTEN short hairpin RNAs (shRNAs) and nonsilencing control in pGIPZ lentiviral vectors that coexpress green fluorescent protein (GFP) were obtained from the MD Anderson shRNA/Open Reading Frame Core Facility. The 293FT cell lines (Invitrogen, Carlsbad, CA) were transfected with the shRNA vector, pCMVR8.74 (22036; Addgene, Cambridge, MA), and pMD2.G (12259; Addgene) using jetPRIME reagent (Polyplus Transfection, New York, NY) for lentiviral packaging. SDC cell lines were infected with lentivirus supernatant in the presence of 8 μg/mL polybrene. After selection with puromycin, GFP sorting were performed at the MD Anderson Flow Cytometry and Cellular Imaging Core Facility to generate stable shRNA cell lines.
Statistical Analysis
Pathologic findings, marker expression levels, and mutational status were evaluated using Fisher exact tests based on the number of comparative groups. A P value of .05 was considered significant. Overall survival curves were created with Kaplan-Meier analysis using GraphPad Prism 6 software (GraphPad Software Inc, La Jolla, CA).
RESULTS
Histopathology
Tumors included 31 de novo SDCs and 12 SDCs arising in carcinoma ex pleomorphic adenoma (Supporting Table 1 ). Tumor cells displayed abundant eosinophilic cytoplasm and central or eccentric large nuclei with checkered chromatin and occasional nuclei. Abnormal mitosis, apoptotic features, and pleomorphism were not uncommon. In some tumors, mucinous, rhabdoid, oncocytoid cellular features were observed. These features were present in both de novo SDCs and in those arising in carcinoma ex pleomorphic adenoma. SDCs manifested strong nuclear staining for androgen receptor in approximately 70% of tumor cells irrespective of their derivation (Supporting Table 1 ), as previously reported.
23
HER2/PI3K Pathway Alterations in SDCs
A screening set of 20 fresh-frozen tumor tissues was tested for PIK3CA, PTEN, and AKT1 mutation analysis using Sanger sequencing. Five of the 20 tumors (20%) had hotspot mutations of the PIK3CA gene. No mutations were observed in the PTEN or AKT1 genes. Various PTEN and p-AKT expression levels were observed in all 20 SDCs on Western blot analysis (Supporting Fig. 1 ). On the basis of these findings, mutation analysis of the PIK3CA gene and IHC analyses of HER2, PTEN, and p-AKT expression were performed on 43 primary SDCs (Fig. 1A,B) . The findings are summarized in Figure 1C (Fig. 1B , right) were identified in 10 tumors and included p.H1047R (c.3140A>G) in 3 SDCs, p.E542K (c.1624G>A) in 5 SDCs, and p.E545K (c.1633G>A) in 2 SDCs. In our study, the p.E542K PIK3CA mutation was the most frequent (Fig. 1B,  right) , and 1 tumor each had p.E81K (c.241G>A) and p.S130_R131del (Fig. 1B, left) mutations (the latter mutation is not cited in the COSMIC database, V75). One tumor (SDC-10) with a p.S130_R131del mutation had a remarkable response to combined treatment with temsirolimus and bevacizumab, as previously reported by our group. 28 Notably, alteration in at least one member of HER2/ PI3K pathway was observed in 37 of 43 tumors (86%), and co-alteration of 2 or more members was identified in 8 of 43 tumors (19%). The most frequent alteration was loss of PTEN expression, which was observed in greater than one-half of tumors (22 of 43 tumors; 51%). HER2 overexpression was identified concurrently with a PIK3CA mutation in only 2 of 12 tumors (17%); and 1 of those tumors (SDC-35) also had PTEN loss, PIK3CA mutation, and HER2 overexpression. Consistent with the convergence of PTEN, PIK3CA, and HER2 alterations in the PI3K pathway, high expression of p-AKT (Fig. 1A [SDC-02 and SDC-24]) was observed in 39 of 43 tumors (91%). Therefore, we empirically classified SDCs (Fig.  1C ) into 4 major groups; group I, tumors with a single alteration (either PTEN loss or PIK3CA mutation); group II, tumors with HER2 overexpression; group III, tumors with more than 2 alterations; and group IV, tumors with no alterations. Table 3 ). Only HER2 overexpression was significantly correlated with lymph node metastasis (P = .04), and PTEN loss was correlated with age (P = .02).
Clinicopathologic Correlations and Survival Status
PI3K Signaling and Response in PTEN-Deficient SDC Cell Lines
To characterize the HER2/PI3K/PTEN pathway in cell lines derived from salivary ductal epithelial carcinomas, we evaluated expression levels of PTEN, HER2, and p-AKT and mutations of PIK3CA and PTEN in the A253, RET981, and MAC cell lines. All 3 cell lines lacked PIK3CA mutation (data not shown). The RET981 and MAC cell lines expressed both PTEN and HER2 proteins ( Fig. 2A, left) , whereas the A253 cell line had loss of PTEN protein ( Fig. 2A, left) together with PTEN mutation (c.455T>C) ( Fig. 2A, right) (also reported in the COSMIC database, V75) and low HER2 protein expression. The A253 cell line expressed higher levels of p-AKT compared with both MAC and RET981 cells, possibly reflecting the status of PTEN. On the basis of these findings, the A253 cell line was considered to represent SDCs with PTEN loss (Fig. 1C, group I) , and the RET981 and MAC cell lines were considered to represent SDCs with intact PTEN and HER2 overexpression (Fig. 1C, group II) .
To determine the effect of PTEN loss on PI3K activation, we stably knocked down PTEN expression (PTEN-kd) in the RET981 and MAC cell lines. Knockdown of PTEN consistently resulted in increase of p-AKT in both PTEN-kd cell lines (Fig. 2B, left) . Two PTEN-kd RET981 clones exhibited significantly increased cell proliferation compared with control cells (Fig. 2B, right) . In contrast, PTEN-kd MAC cells exhibited comparatively higher cell proliferation than control cells. Thus, knockdown of PTEN led to PI3K activation in both RET981 and MAC cells. Therefore, we empirically considered PTEN-kd of both RET981 and MAC cells to mimic tumors with concurrent PTEN loss and HER2 overexpression (Fig. 1C, group III) .
Because epithelial malignances with PTEN loss have been associated with PI3Kβ activation, 29, 30 we investigated the effect of PTEN loss on response to PI3Kβ inhibitors in our cell lines. The effect of AZD8186 (PI3Kβ and PI3Kδ inhibitor) on A253 cells and LNCaP cells (prostate cancer cell line with a mutation and one allele deletion of the PTEN gene) was evaluated. Treatment of LNCaP cells with AZD8186 (0.25 μM) resulted in a reduction of cell proliferation (Fig. 3A, top) and the inhibition of p-AKT expression 3 hours after treatment, with rebound of p-AKT expression at 12 hours (Fig. 3A , bottom), in agreement with a previous report. 31 In contrast, treatment with AZD8186 at different doses in the A253 cells line produced minimal or no effect on cell growth or p-AKT expression (Fig. 3B) . Similarly, treatment with a different PI3Kβ inhibitor (GSK2636771) had no effect on A253 cell proliferation (Fig. 3C) . These results indicate that targeting the PI3Kβ isoform alone had no effect on the proliferation of A253 cells (PTEN loss and low HER2 expression).
To assess the role of PI3Kα isoform activation on cell proliferation, we treated A253 cells with BYL719 (PI3Kα inhibitor). BYL719 at 5 μM produced no changes in proliferation or p-AKT protein levels in A253 cells (Fig. 3D,E) . To determine whether inhibition of both the PI3Kα and PI3Kβ isoforms affected cell kinetics, we treated A253 cells with a combination of PI3Kα (BYL719) and PI3Kβ (AZD8186) inhibitors and with pan-PI3K (PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ) inhibitor (GDC-0941). Combined PI3Kα and PI3Kβ treatment and pan-PI3K treatment at 2.5 μM produced no demonstrable changes in A253 cell proliferation (Fig. 3D, right) . However, treatment at 5 μM resulted in significant reductions in cell proliferation and p-AKT expression compared with dimethyl sulfoxide controls (Fig. 3D,E) . The results suggest that patients who have SDC with loss of PTEN and low HER2 expression (group I) may respond to combined PI3Kα and PI3Kβ inhibitors or pan-PI3K inhibitor.
To investigate the association of HER2 overexpression and intact PTEN (group II) in response to PI3K inhibitors, we treated HER2-expressing cell lines (RET981 and MAC) with PI3Kα and PI3Kβ inhibitors either alone or in combination and with the pan-PI3K inhibitor. We observed various responses to individual and combined PI3K inhibitors between both cell lines. The RET981 cell line exhibited partial suppression of proliferation at 2.5 μM and complete suppression in response to 5 μM PI3Kα and/or PI3Kβ inhibitor (either alone or in combination) or to 5 μM pan-PI3K inhibitor (Fig. 4A) . In contrast, MAC cells exhibited only a partial reduction in cell proliferation at 5 μM with pan-PI3K inhibitor or the combined PI3Kα and PI3Kβ inhibitors, but not with PI3Kα or PI3Kβ inhibitor alone (Fig. 4B) . These findings suggest that SDCs with intact PTEN and HER2 overexpression (group II) may respond to combined PI3Kα and PI3Kβ inhibitors or to a pan-PI3K inhibitor.
To assess whether PTEN loss in HER2-overexpressing cells influences response to PI3K inhibitors (Fig. 1C, group III) , we treated PTEN-kd RET981 and MAC cells with PI3K inhibitors. PTEN-kd RET981 (35) 10 (23) 8 (19) 17 (40) 10 (23) 15 (35) No 3 (7) 5 (12) .42 3 (7) 5 (12) 1.00 2 (5) 6 (14) .68 LN Met Yes 15 (35) 17 (40) 9 (21) 23 (54) 12 (28) 20 (47) No 6 (14) 4 (9) .72 3 (7) 7 (16) 1.00 0 (0) 10 (23) .04 Rec/Met Yes 11 (26) 15 (35) 6 (14) 20 (47) 9 (21) 17 (40) No 9 (21) 7 (16) . 53 5 (12) 11 (26) .72 3 (7) 13 (30) .32 p-AKT (IHC) Positive 18 (42) 21 (49) 11 (26) 28 (65) 11 (26) 28 (65) Negative 3 (7) 1 (2) . 35 1 (2) 3 (7) 1.00 1 (2) 3 (7) 1.00 Cancer September 15, 2018 cell proliferation was reduced by treatment with 5 μM AZD8186 (PI3Kβ inhibitor) or BYL719 (PI3Kα inhibitor) either alone or in combination, and with GDC-0941 (pan-PI3K inhibitor) (Fig. 5A) , while p-AKT expression was markedly reduced (Fig. 5B) , similar to what was observed in parental RET981 cells (Fig. 4A) . In contrast, MAC PTEN-kd cells exhibited no response to PI3Kα and PI3Kβ inhibitors but displayed partial suppression of cell proliferation to combined PI3Kα and PI3Kβ inhibitors and to pan-PI3K inhibitor (Fig. 5C) . Similarly, p-AKT expression in MAC PTEN-kd cells was reduced by combined PI3Kα and PI3Kβ inhibitors and by pan-PI3K inhibitor (Fig. 5D) . Together, these results suggest that all SDC tumor groups potentially could respond to the combined PI3Kα and PI3Kβ inhibitors or to the pan-PI3K inhibitor. 
A253 (group 1)
Cancer September 15, 2018 DISCUSSION Biomarker-based stratification of patients for small molecules targeting critical pathways associated with SDC development and progression may lead to sustained response in certain patients. 32, 33 Our study of the HER2/ PI3K pathway revealed frequent and reciprocal alterations of HER2 and key components of the PI3K pathway in the majority of patients with SDC. We also provide evidence that certain patients who have SDC with HER2/ PI3K pathway abnormalities may benefit from treatment with combined PI3Kα and PI3Kβ inhibitors or with pan-PI3K inhibitor. The results also highlight the dominant loss of PTEN expression in SDCs, sustaining previous IHC-based findings in salivary (Supporting Table 4 ) and various epithelial malignancies. 11, 13, 21, [34] [35] [36] [37] Together, these data advance the use of IHC as a reliable tool in the determination of PTEN protein loss in SDC irrespective of the genetic, epigenetic, and/or posttranscriptional modifications of this gene. 21, 38 Consistent with previous studies of SDCs (Supporting Table 4 ) and mammary ductal carcinomas, high HER2 expression was identified in 25% of SDCs either alone or concurrently with different PI3K alterations. This sustains the finding that HER2 status may allow for the stratification of a subset of patients to either anti-HER2 or PI3K inhibitors based on the presence or absence of other PI3K pathway alterations. [39] [40] [41] [42] [43] [44] Similarly, PIK3CA missense mutations at known hot spots were observed in a certain subset of tumors, confirming previous studies in SDCs 11, [45] [46] [47] (Supporting Table 4 ) and other carcinomas. 17, 18, 36, [48] [49] [50] [51] [52] [53] [54] Although 4 tumors (9%) had concurrent PTEN loss and PIK3CA mutation, the significance of these findings cannot be determined because of the lack of PIK3CA mutation in salivary cell lines. It is noteworthy that the limited simultaneous occurrence of both alterations in SDC is at variance with what has been reported in endometrial carcinoma studies, in which PTEN loss and PIK3CA mutation more frequently were observed together. 50 These results underscore the considerable inter-tumor variations and suggest a different context for the association between tumors and PI3K alterations that may impact the therapeutic stratification of patients with SDC. [55] [56] [57] [58] For the first time, our current in vitro findings provide evidence for a direct link between PTEN loss and PI3K activation and a potential response to PI3K inhibitors. The data indicate that loss of PTEN in salivary cell lines is invariably associated with the hypothesis that PI3K activation sustains an important role in SDC tumorigenesis. 22, 34, 59 It also is worth noting that salivary cell lines with PTEN loss did not respond to PI3Kβ selective inhibitors, contrary to their reported dependence on the PI3Kβ isoform in PTEN-deficient tumors. 29, 30 However, that response was achieved by combined PI3Kα and PI3Kβ inhibitors or by a pan-PI3K inhibitor, suggesting a reciprocal relation between PI3Kα and PI3Kβ activities. Similar findings recently were reported in PTEN-deficient prostate and breast cancer cell lines and were attributed to functional interactions of the PI3Kα and PI3Kβ isoforms. 31, 60 In contrast to SDC cells, head and neck squamous cell carcinoma cells with PTEN loss were commonly resistant to pan-PI3K inhibitor, indicating differences in tumor context. 61 Contrary to previous reports of the involvement of HRas proto-oncogene, GTPase (HRAS) gene mutation in one-third of SDCs, [45] [46] [47] 62 we identified no HRAS mutations in the current cohort (Supporting Tables 4 and 5 ). Together with the lack of cell lines that had mutations of HRAS gene, the current results suggest a minimal functional role for HRAS in SDC tumorigenesis. We note that a marked clinical response to combined treatment with temsirolimus and bevacizumab was achieved in 1 of the patients with SDC in our cohort who had a tumor with a PIK3CA mutation. 28 Collectively, our findings demonstrate the common occurrence of PI3K alterations in SDC and a potential for the substratification of patients based on PI3K marker status for targeted PI3K therapy. 59 Together with our findings in cell lines, the data suggest that patients can be stratified based on alterations of the PI3K pathway and can be categorized empirically as follows: 1) patients with a single alteration (group I) would be stratified to treatment with a pan-PI3K inhibitor, 2) patients with HER2 overexpression only (group II) would be stratified to treatment with trastuzumab or a pan-PI3K inhibitor, 3) patients with more than 2 alterations (group III) would be stratified to combined anti-HER2 and pan-PI3K therapy, and 4) patients with no alterations (group IV) would be stratified to conventional therapy. In this study, only a few tumors lacked p-AKT expression, but the significance and the underlying cause for the loss of this marker remain to be determined. We also observed no significant association between PI3K alterations and patient outcomes, likely because of the underlying aggressive nature of this disease. These findings are concordant with those from previous studies and highlight the short-term survival of patients with SDC regardless of which conventional therapy they receive. 8, 28, 63, 64 In summary, our current study demonstrates the activation of HER2/PI3K alterations in the majority of patients with SDC and provides evidence for a potential response to combined PI3Kα and PI3Kβ targeted therapy or to pan-PI3K targeted therapy in these patients. 
